What is included in this Sample?
- * Market Segmentation
- * Key Findings
- * Research Scope
- * Table of Content
- * Report Structure
- * Report Methodology
Download FREE Sample Report
Plasminogen Market Size, Share, Growth, And Industry Analysis, By Type (Intravenous Injection, Eye Drops), By Application (Ligneous Conjunctivitis, Diabetic Foot, Wound Healing, Others) and Regional Forecast From 2025 To 2033
Trending Insights

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels
PLASMINOGEN MARKET OVERVIEW
The global Plasminogen Market size is USD 15.91 billion in 2024 and is expected to reach USD 24.26 billion by 2033, growing at a compound annual growth rate (CAGR) of about 4.8% during the forecast period.
The COVID-19 pandemic has been unprecedented and staggering, with plasminogen experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.
Plasminogen is a glycoprotein that plays a crucial role in the regulation of blood clotting and fibrinolysis. It is synthesized and secreted by the liver into the bloodstream as an inactive precursor enzyme called plasminogen. Plasminogen circulates in the blood, maintaining a balance between clot formation and clot dissolution. When a blood vessel is damaged, a complex series of reactions known as the coagulation cascade is initiated, leading to the formation of a blood clot. Plasminogen is activated to plasmin, an active protease enzyme, by several activators, including tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). Once activated, plasmin acts on fibrin, the major component of blood clots, and breaks it down into smaller fragments, resulting in the dissolution of the clot. Plasminogen also plays a role in various physiological and pathological processes. It is involved in tissue remodeling, wound healing, and the clearance of extravascular fibrin deposits. In addition to its fibrinolytic activity, plasminogen has been found to participate in cell migration, inflammation, and angiogenesis. Abnormalities in the plasminogen system have been associated with various diseases, including thrombosis, cardiovascular diseases, and certain types of cancer.
The plasminogen market is experiencing significant growth and is expected to continue its upward trajectory in the coming years. Plasminogen is a protein found in the human body that plays a crucial role in the fibrinolytic system, which is responsible for breaking down blood clots. Plasminogen is used in various therapeutic applications, including the treatment of disorders such as congenital plasminogen deficiency and the management of severe burns and wounds.
COVID-19 IMPACT
Pandemic Resulted in an Increased Focus on Research and Development Activities Boosted the Market Growth
The COVID-19 pandemic has had a substantial impact on the healthcare industry, including the plasminogen market. The outbreak of the pandemic resulted in an increased focus on research and development activities to find effective treatments for COVID-19 patients. Plasminogen has emerged as a potential therapeutic option for the management of COVID-19-related complications, particularly in patients with severe lung damage and blood clotting disorders. The demand for plasminogen has witnessed a surge as a result of these developments. Additionally, the disruptions in the global supply chain due to lockdowns and restrictions have affected the production and distribution of plasminogen, leading to temporary supply shortages in some regions.
LATEST TRENDS
Increasing Adoption of Recombinant Plasminogen to Boost the Market Development
Recombinant plasminogen is produced through genetic engineering techniques, offering advantages such as high purity, consistent quality, and enhanced safety profile compared to traditional plasma-derived plasminogen. The growing preference for recombinant plasminogen is driven by its improved efficacy and reduced risk of contamination. This trend is expected to shape the market landscape as more companies invest in research and development to develop recombinant plasminogen products.
PLASMINOGEN MARKET SEGMENTATION
By Type Analysis
According to type, the market can be segmented into intravenous injection, eye drops. Intravenous Injection being the leading segment of the market by type analysis.
By Application Analysis
Based on application, the market can be divided into ligneous conjunctivitis, diabetic foot, wound healing, others. Ligneous conjunctivitis being the leading segment of the market by application analysis.
DRIVING FACTORS
Growing Prevalence of Plasminogen Deficiency Disorders to Drive the Market Growth
Plasminogen deficiency disorders, such as congenital plasminogen deficiency, are rare genetic conditions that result in abnormal clot formation and impaired wound healing. The increasing prevalence of these disorders is driving the demand for plasminogen therapy. The rising awareness, improved diagnostics, and availability of advanced treatment options are factors contributing to the growth of the plasminogen market.
Increasing Application in Wound Healing and Tissue Regeneration to Drive the Market Development
Plasminogen plays a crucial role in wound healing and tissue regeneration processes. It promotes the breakdown of fibrin and facilitates the removal of necrotic tissues, thereby promoting the formation of new tissues. The growing adoption of plasminogen therapy in the management of severe burns, chronic wounds, and diabetic ulcers is driving the demand for plasminogen products. The focus on advanced wound care and the need for effective therapies to enhance the healing process are key drivers for the market.
RESTRAINING FACTORS
High Cost Associated with Plasminogen Therapy to Hamper the Market growth
The production and purification processes involved in manufacturing plasminogen products are complex and expensive. This leads to higher prices of plasminogen therapy, limiting its accessibility, particularly in developing regions with limited healthcare budgets. The challenge lies in striking a balance between ensuring the affordability of plasminogen therapy and maintaining the profitability for manufacturers.
-
Request a Free sample to learn more about this report
PLASMINOGEN MARKET REGIONAL INSIGHTS
Well-Established Healthcare Infrastructure and The Increasing Prevalence of Plasminogen Deficiency Disorders in North America to Bolster the Market Development in the Region
North America is a significant market for plasminogen due to its well-established healthcare infrastructure and the increasing prevalence of plasminogen deficiency disorders in the region. The region is known for its advanced medical facilities, research capabilities, and access to cutting-edge technologies. This enables the efficient diagnosis and treatment of plasminogen deficiency disorders, leading to a higher demand for plasminogen products. The rising prevalence of plasminogen deficiency disorders in North America is a driving factor for market growth. These disorders, including congenital plasminogen deficiency, can lead to various complications such as impaired wound healing, excessive scarring, and vision impairments. As awareness about these disorders increases and diagnostic techniques improve, more cases are being identified, resulting in a higher demand for plasminogen therapy.
Europe is a prominent market for plasminogen, driven by the increasing awareness about plasminogen deficiency disorders and the availability of advanced treatment options. European countries have implemented robust healthcare systems with comprehensive coverage, ensuring access to plasminogen therapy for patients in need. The awareness about plasminogen deficiency disorders has been steadily growing in Europe. Efforts by healthcare organizations, patient advocacy groups, and medical professionals have led to increased recognition of these rare genetic conditions. As a result, more patients are being diagnosed with plasminogen deficiency disorders, creating a higher demand for plasminogen therapy.
KEY INDUSTRY PLAYERS
Key Players Focus on Partnerships to Gain a Competitive Advantage
Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.
List of Top Plasminogen Companies
- Kedrion (Italy)
- Prometic (Canada)
- Genentech (Roche) (U.S.)
- Boehringer Ingelheim (Germany)
- Kyowa Hakko Kirin (Japan)
- Omeros Corporation (U.S.)
REPORT COVERAGE
This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.
Attributes | Details |
---|---|
Market Size Value In |
US$ 15.91 Billion in 2024 |
Market Size Value By |
US$ 24.26 Billion by 2033 |
Growth Rate |
CAGR of 4.8% from 2025 to 2033 |
Forecast Period |
2025-2033 |
Base Year |
2024 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
|
By Type
|
|
By Application
|
FAQs
The global plasminogen size is expected to reach USD 24.26 billion by 2033.
The plasminogen is expected to exhibit a CAGR of 4.8% by 2033.
Growing prevalence of plasminogen deficiency disorders and increasing application in wound healing & tissue regeneration are the driving factors of the market.
The dominating companies in the market are Kedrion, Prometic, Genentech (Roche), Boehringer Ingelheim and Kyowa Hakko Kirin.